SOLENO THERAPEUT. DL-001 (6XC F) stock market data APIs
€28.4338
-0.12(-0.4%)
as of March 20, 2026
Try our APIs with
free plan!
SOLENO THERAPEUT. DL-001 Financial Data Overview
Price chart is built with
Anychart
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Prev. Close
28.4338
Open
28.31
High
28.7404
Low
27.9233
52 wk Range
27.54-76.65
Market Cap
1 604 M
P/E Ratio
83.8235
Shares Outstanding
51 624 K
Revenue
190 M
Beta
-3.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SOLENO THERAPEUT. DL-001 data using free add-ons & libraries
Get SOLENO THERAPEUT. DL-001 Fundamental Data
SOLENO THERAPEUT. DL-001 Fundamental data includes:
- Net Revenue: 190 M
- EBITDA: 16 967 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: 0.34
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SOLENO THERAPEUT. DL-001 News
New
A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Soleno Therapeutics (SLNO) is back in focus after an Oppenheimer report flagged...
Sector Update: Health Care Stocks Slip Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says
Soleno Therapeutics (SLNO) is expected to see a slower US launch for Vykat XR, but 2026 sales could PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price ta...
Get SOLENO THERAPEUT. DL-001 fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
